Earnings Preannouncement for 2025
Filed with SSE · · 2 pages · Chinese
Mabwell (Shanghai) Bioscience Co., Ltd. on 6ix
Earlier from Mabwell (Shanghai) Bioscience
- Mabwell Announces First-Patient Dosed in Clinical Trial of Novel CDH17-Targeting ADC 7MW4911 in the U.S.
- Announcement on Continuing to Use Some Temporarily Idle Raised Funds for Cash Management
- Mabwell's Adalimumab Biosimilar Receives Marketing Approval in Indonesia
- Mabwell Announces First Patient Dosed in Phase II Trial of Anti-IL-11 Antibody for Pathological Scarring
- Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025
Later from Mabwell (Shanghai) Bioscience
- Notice on Convening the 1st Extraordinary General Meeting in 2026
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
- Announcement on Preliminary Earnings Estimate for 2025
- Announcement on the Results of Issuance of the 2026 Phase I Targeted Science and Technology Innovation Bonds
- 2025 Annual Report
Follow Mabwell (Shanghai) Bioscience into a list and get an email when it puts out news.
Follow Mabwell (Shanghai) Bioscience